118 related articles for article (PubMed ID: 35046292)
1. [A Case of Unresectable Recurrent Colorectal Cancer with Regorafenib Treatment and Long-Term Survival].
Maruo H; Sato S; Nakamura T; Sekimori K; Obayashi M; Hayashi Y; Ishimatsu H; Shoji T; Hirayama K; Yamazaki M
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1670-1672. PubMed ID: 35046292
[TBL] [Abstract][Full Text] [Related]
2. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Long-Term Survival after Administration of Regorafenib for Stage Ⅳ Colorectal Cancer].
Kono T; Yokokawa H; Miyano Y; Oyama K; Yoshimatsu K; Koike T; Shiozawa S
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1278-1280. PubMed ID: 34657063
[TBL] [Abstract][Full Text] [Related]
4. Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report.
Kikuchi K; Ogawa M; Sasaki A
J Med Case Rep; 2024 Feb; 18(1):45. PubMed ID: 38321556
[TBL] [Abstract][Full Text] [Related]
5. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
[TBL] [Abstract][Full Text] [Related]
9. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
[TBL] [Abstract][Full Text] [Related]
13. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
[TBL] [Abstract][Full Text] [Related]
14. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
[TBL] [Abstract][Full Text] [Related]
15. FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.
Adenis A; Mazard T; Fraisse J; Chalbos P; Pastor B; Evesque L; Ghiringhelli F; Mollevi C; Delaine S; Ychou M
BMC Cancer; 2021 May; 21(1):564. PubMed ID: 34001059
[TBL] [Abstract][Full Text] [Related]
16. [Long-Term Survival of a Patient with Metastatic Liver and Para-Aortic Lymph Node Cancer from Colon Cancer Treated with Regorafenib].
Watanabe N; Akagi S; Inoue H; Nakatsuji H; Ito H; Toma A; Nakamura K; Ochiai T; Otsuji E
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1732-1734. PubMed ID: 29394758
[TBL] [Abstract][Full Text] [Related]
17. Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis.
Nakashima M; Takeuchi M; Tanaka S; Kawakami K
Anticancer Res; 2021 Feb; 41(2):1055-1062. PubMed ID: 33517315
[TBL] [Abstract][Full Text] [Related]
18. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
[TBL] [Abstract][Full Text] [Related]
19. The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression.
Roberto M; Falcone R; Mazzuca F; Archibugi L; Castaldi N; Botticelli A; Osti MF; Marchetti P
Medicine (Baltimore); 2017 Dec; 96(48):e9023. PubMed ID: 29310420
[TBL] [Abstract][Full Text] [Related]
20. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
